Who is sponsoring HUTONG?

HUTONG is sponsored by Hoffmann-La Roche.

What condition does HUTONG study?

HUTONG studies Neovascular Age-related Macular Degeneration, nAMD.

What drugs are being tested in HUTONG?

Interventions: PDS With Ranibizumab (100 mg/mL), Ranibizumab (10 mg/mL).

What is the status of HUTONG?

HUTONG is currently RECRUITING.

Last reviewed 2026-02-02 · How we verify

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) (HUTONG)

NCT05562947 PHASE3 RECRUITING

This study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with ranibizumab 0.5 milligrams (mg) delivered every 4 weeks (Q4W) as intravitreal (IVT) injection in chinese participants with nAMD.

Details

Lead sponsor	Hoffmann-La Roche
Phase	PHASE3
Status	RECRUITING
Enrolment	68
Start date	Mon Jun 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Aug 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Neovascular Age-related Macular Degeneration
nAMD

Interventions

PDS With Ranibizumab (100 mg/mL)
Ranibizumab (10 mg/mL)

Countries

China